LIXTE Biotechnology (NASDAQ: LIXT) Releases Preclinical Results of Cancer Treatment LB-100 Showing Strong Anti-Cancer Activity with Novel Drug Combinations
LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) is engaged as a clinical-stage pharmaceutical company, which is focused on the research, development ...